NEWS
First Patients in U.S. Treated with Distalmotion’s Dexter Surgical Robot in the Outpatient Setting
October 28 , 2024 Distalmotion’s Dexter Surgical Robot opens an entire new era for soft tissue robotics in the outpatient setting and ambulatory surgery centers that will have immediate benefit for patients. Distalmotion has been granted De Novo approval by the U.S. Food and Drug Administration (FDA) to market the Dexter Surgical Robot for … Read more
EP #453 – Samir Ounzain: Unlocking the Power of the Dark Genome
This episode was sponsored by smzh, your independent go-to partner in all matters relating to finance. About Samir Ounzain: Samir Ounzain is the co-founder and CEO of HAYA Therapeutics, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at … Read more
Reprogramming the software of the cell to fight disease
HAYA Therapeutics is using its unparalleled regulatory genome atlas and innovative proprietary platform to identify novel long non-coding RNAs and develop drug candidates that return diseased cells back to healthy states. Heart failure and many other common and chronic diseases that have a huge impact on society can be driven by lifestyle-related risk factors. A … Read more
FDA Grants De Novo Marketing Authorization for the Distalmotion Dexter® Surgical Robot
October 28 , 2024 Distalmotion, a pioneer in surgical robotics, proudly announces the achievement of a significant milestone: surpassing 1000 successful procedures with its surgical robot, Dexter. Since its first commercial installation in 2022, Dexter has become a cornerstone in surgical innovation, treating patients everyday across multiple countries and institutions. Distalmotion has been granted … Read more
STALICLA – Une révolution dans la médecine de précision pour l’autisme
La médecine de précision redéfinit notre approche de la psychiatrie, notamment pour les troubles complexes comme l’autisme GrandAngle, Octobre 11, 2024 – Fondée en 2017 à Genève, STALICLA se distingue comme pionnière dans ce domaine. L’entreprise regroupe une trentaine de médecins chercheurs spécialisés en neuro-sciences et biologie moléculaire, opérant en Suisse, à Barcelone et à Boston. … Read more
HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform
LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more
Franklin Servan-Schreiber, de Transmutex: «Notre bataille consiste à rendre le nucléaire plus acceptable»
Building on Existing Technologies for a Commercial Prototype Within a Decade Le directeur de la start-up genevoise estime que l’atome peut contribuer à lutter contre le réchauffement climatique tout en fournissant une quantité d’électricité extraordinaire. Transmutex veut réduire la durée de vie des déchets de 300 000 à 300 ans L’annonce jeudi du Conseil fédéral selon laquelle … Read more
HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer
LAUSANNE, Switzerland and SAN DIEGO – July 15, 2024 – HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO). With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in … Read more
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics July 9, 2024 Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today … Read more
This new technology for nuclear power could help fuel the AI revolution
Building on Existing Technologies for a Commercial Prototype Within a Decade A Swiss startup says it has pioneered a way to reduce radioactive waste from nuclear plants — which could help power data centers. Jason marz/1368745971/Getty Images Swiss startup Transmutex’s technology reduces long-term radioactive waste. The technology could further entice AI companies to use nuclear energy … Read more
